WEB | Are Your Products in TGA’s Compliance Spotlight for 2026–2027?

The Therapeutic Goods Administration (TGA) has recently issued its regulatory spotlights for the upcoming years to support companies in ensuring their regulatory compliance. 

In this fast‑paced 1‑hour session, Anne Arndt from our Health Cluster Member Elevate Medtech will unpack what the TGA’s new proactive, risk‑based compliance principles really mean for products in the regulator’s priority focus areas. 

We’ll explore how these principles are expected to play out across different product types and how they are likely to shape regulatory scrutiny. Rather than diving into technical detail, we’ll zoom out to focus on the practical implications for sponsors and advertisers.

 You’ll walk away with a clear, big‑picture view of where compliance scrutiny is likely to intensify in 2026–2027, along with practical prompts to start sense‑checking your own portfolio against these evolving expectations.